Generics | pharmaphorum

Skip to main content

Thursday 21 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Generics

News

TevaCanada2

Teva sells women's health division to tackle $35bn debts

Teva has sold its women’s health business in order to pay off some of its $35 billion in debts built up in acquiring Allergan’s generics business.

News

TevaCanada2

Bidders lining up for Teva women's health unit

Allergan generics buyout left Teva with $35m debts

News

FDA's Gottlieb reveals plans to tackle generic price abuses

Tackling high drug prices is priority for Trump administrations.

News

TevaCanada2

Teva's CEO Vigodman steps down

Firm searches for new leader, chairman takes over on interim basis.

Views & Analysis

Old typewriter patent stamp. OCTOBER 1894

Making the case for pharmaceutical IP management

IP management can protect pharma companies’ investments and future R&D.

News

European Medicines Agency London

EU drug regulators concerned about Brexit impact

European regulators concerned over impact of EMA move.

Load more results

Editor's Picks

BMS signs $15.2bn R&D alliance with China's Hengrui

UK Health Secretary resigns, sparking leadership speculation

Reports: Makary out, Diamantas in as FDA commissioner

EU agrees plan to tackle essential medicine shortages

Clock starts ticking on UK's single patient record plan

News

Bayer gets swift review for Kerendia in type 1 diabetes

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company